Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.53 +3.09%

+$0.08 today

Market cap
$297.72M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.25M

Average 3.81M

Income Statement

Follow revenue through to earnings.

Revenue

$41,000.00

FY 2025 · Annual

+105.0% YoY

Operating Income

-$94.49M

FY 2025 · Annual

Net Income

-$88.09M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

ALT Earnings Waterfall · TTM

NASDAQ:ALT · Revenue to Net Income

Key Ratios

EPS$-0.93
Gross Margin-74725.0%
Net Margin-232105.8%
P/E Ratio-3.9
P/S Ratio36113.7

Analysis

$36.0K of revenue converted into -$91.1M of net income for the selected period. Gross margin is -74725.0% and net margin is -232105.8%, showing how much revenue survives after costs and taxes. EPS is $-0.93, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
10-QQuarterly reportNov 12, 2026

How much revenue does ALT generate?

Altimmune, Inc. (ALT) reported $41,000.00 of revenue in fiscal 2025.

Is ALT profitable?

Altimmune, Inc. (ALT) reported -$88.09M of net income, with a net margin of -214861.0%.